醫管局藥物名冊 [只備英文版]
1.藥物可能以學術名稱或專利名稱標示。名冊所列的品牌藥名只供參考之用，並不代表供應有關品牌製品。
2.由於藥物可有不同劑型或臨床應用，部分名冊藥物可能會出現於多個藥物類別。
3.專用藥物需要在特定的臨床應用及臨床情況適用下處方。
4.不同聯網/醫院會按其運作及服務需要，庫存醫管局藥物名冊內適當的藥物。
| 通用藥物 | 專用藥物 | 獲安全網資助的 自費購買藥物(自費藥物) |
不獲安全網資助的 自費藥物 |
|---|---|---|---|
 癌瘤及免疫系統
|
|||
| 通用藥物 | 專用藥物 | 獲安全網資助的 自費購買藥物(自費藥物) |
不獲安全網資助的 自費藥物 |
| CYTOTOXIC DRUGS | |||
| ACTINOMYCIN D | ARSENIC TRIOXIDE | ABEMACICLIB | ACALABRUTINIB |
| ASPARAGINASE | BLINATUMOMAB | ACALABRUTINIB | APALUTAMIDE |
| BLEOMYCIN | BUSULPHAN | AFATINIB | ATEZOLIZUMAB |
| CALCIUM FOLINATE | CETUXIMAB | ALECTINIB | AVELUMAB |
| CAPECITABINE | CLADRIBINE | ATEZOLIZUMAB | BEVACIZUMAB |
| CARBOPLATIN | CLOFARABINE | AXITINIB | BORTEZOMIB |
| CARMUSTINE | CRISANTASPASE (ASPARAGINASE ERW) | AZACITIDINE | BRENTUXIMAB VEDOTIN |
| CHLORAMBUCIL | DASATINIB | BENDAMUSTINE | CABOZANTINIB (CABOMETYX) |
| CISPLATIN | ERIBULIN | BEVACIZUMAB | CARFILZOMIB |
| CYCLOPHOSPHAMIDE | ERLOTINIB | BORTEZOMIB | CETUXIMAB |
| CYTARABINE | EVEROLIMUS (AFINITOR) (OR EQUIV) | BRENTUXIMAB VEDOTIN | DACOMITINIB |
| DACARBAZINE | FLUDARABINE | BRIGATINIB | DARATUMUMAB |
| DAUNORUBICIN | IFOSFAMIDE | CARFILZOMIB | DOXORUBICIN (LIPOSOMAL) |
| DOCETAXEL | IMATINIB | CERITINIB | ESTRAMUSTINE |
| DOXORUBICIN | MITOXANTRONE | CETUXIMAB | EVEROLIMUS (AFINITOR) (OR EQUIV) |
| EPIRUBICIN | PEGASPARAGINASE | CRIZOTINIB | GILTERITINIB |
| ETOPOSIDE | PEMETREXED | DABRAFENIB | IBRUTINIB |
| FLUOROURACIL | TEMOZOLOMIDE | DARATUMUMAB | IPILIMUMAB |
| GEMCITABINE | THIOTEPA | DASATINIB | ISATUXIMAB |
| HYDROXYUREA | TOPOTECAN | DOXORUBICIN (LIPOSOMAL) | LENVATINIB |
| IDARUBICIN | TRASTUZUMAB | DURVALUMAB | MIDOSTAURIN |
| IRINOTECAN | TS-1 (OR EQUIV) | EVEROLIMUS (AFINITOR) (OR EQUIV) | NIRAPARIB (TOSYLATE) |
| LOMUSTINE | VINORELBINE | GEFITINIB | NIVOLUMAB |
| MELPHALAN | GEMTUZUMAB | OBINUTUZUMAB | |
| MERCAPTOPURINE | IBRUTINIB | OLAPARIB | |
| MESNA | INOTUZUMAB OZOGAMICIN | PACLITAXEL (ALBUMIN) | |
| METHOTREXATE | IPILIMUMAB | PAZOPANIB | |
| MITOMYCIN | IXAZOMIB | PEMBROLIZUMAB | |
| MITOTANE | LAPATINIB | PERTUZUMAB + TRASTUZUMAB | |
| OXALIPLATIN | LENVATINIB | POLATUZUMAB VEDOTIN | |
| PACLITAXEL | LORLATINIB | REGORAFENIB | |
| PROCARBAZINE | MIDOSTAURIN | RUXOLITINIB | |
| THIOGUANINE | NERATINIB | SORAFENIB | |
| TRETINOIN | NILOTINIB | SUNITINIB | |
| VINBLASTINE | NIRAPARIB (TOSYLATE) | TRASTUZUMAB DERUXTECAN | |
| VINCRISTINE | NIVOLUMAB | TRASTUZUMAB EMTANSINE | |
| OBINUTUZUMAB | TRIFLURIDINE + TIPIRACIL | ||
| OLAPARIB | VENETOCLAX | ||
| OSIMERTINIB | ZANUBRUTINIB | ||
| PALBOCICLIB | |||
| PANITUMUMAB | |||
| PAZOPANIB | |||
| PEMBROLIZUMAB | |||
| PERTUZUMAB | |||
| PERTUZUMAB + TRASTUZUMAB | |||
| POLATUZUMAB VEDOTIN | |||
| PONATINIB | |||
| RIBOCICLIB | |||
| RUXOLITINIB | |||
| SORAFENIB | |||
| SUNITINIB | |||
| TEMOZOLOMIDE | |||
| TRAMETINIB | |||
| TRASTUZUMAB | |||
| TRASTUZUMAB EMTANSINE | |||
| VEMURAFENIB | |||
| DRUGS AFFECTING THE IMMUNE RESPONSE | |||
| AZATHIOPRINE | ALEMTUZUMAB (LEMTRADA) | CANAKINUMAB | LENALIDOMIDE |
| BCG | ANTITHYMOCYTE IMMUNOGLOBULIN | CLADRIBINE (MAVENCLAD) | MEPOLIZUMAB |
| THALIDOMIDE | BASILIXIMAB | INTERFERON GAMMA | POMALIDOMIDE |
| CYCLOSPORIN A | LENALIDOMIDE | RITUXIMAB | |
| CYCLOSPORIN A (NEORAL) | NATALIZUMAB | SILTUXIMAB | |
| CYCLOSPORIN A (TEVA) | POMALIDOMIDE | ||
| DIMETHYL FUMARATE | RITUXIMAB | ||
| EVEROLIMUS (CERTICAN) (OR EQUIV) | SIPONIMOD | ||
| FINGOLIMOD | |||
| INTERFERON BETA | |||
| MYCOPHENOLATE | |||
| OFATUMUMAB | |||
| PEGINTERFERON ALFA | |||
| RITUXIMAB | |||
| SIROLIMUS | |||
| TACROLIMUS | |||
| TERIFLUNOMIDE | |||
| SEX HORMONES AND HORMONE ANTAGONISTS IN MALIGNANT DISEASE | |||
| LETROZOLE | ANASTROZOLE | ABIRATERONE | ABIRATERONE |
| MEDROXYPROGESTERONE ACETATE | BICALUTAMIDE | ENZALUTAMIDE | ENZALUTAMIDE |
| MEGESTROL | BUSERELIN | FULVESTRANT | |
| OCTREOTIDE | CYPROTERONE | ||
| SOMATOSTATIN | DEGARELIX | ||
| TAMOXIFEN | EXEMESTANE | ||
| FLUTAMIDE | |||
| GOSERELIN | |||
| LANREOTIDE | |||
| LEUPRORELIN | |||
| OCTREOTIDE | |||
| PASIREOTIDE | |||
| TRIPTORELIN | |||